Frazier Healthcare Partners has announced Mimi Hancock, Ph.D. has joined its Life Sciences team as a Senior Advisor to assist with attracting top talent for Frazier companies. The Frazier Life Sciences team targets two-thirds of its investments in company creation and early-stage opportunities, where building a top leadership team is critical.

Dr. Hancock has over 20 years of experience in the executive search industry. Prior to joining Frazier, she was a member of Spencer Stuart’s Life Sciences Practice. Her executive search experience included assignments for organizations ranging from emerging life sciences companies to multinational biotechnology, pharmaceutical and medical technology firms. She executed searches for board members, and senior executives in general management and R&D, as well as a variety of commercial, finance and business development positions.

Dr. Hancock previously served as Vice President of Operations and co-founder at Avigen, a startup gene therapy company. Prior to that, she was the Director of Cell Biology at Somatix Therapy Corporation, a publicly-held gene therapy company. Earlier in her career, Dr. Hancock worked at Triton Biosciences, where she conducted pioneering research on a novel therapeutic approach targeting the Her2 protein in breast and ovarian cancer. She began her career in healthcare with Peralta Cancer Research Institute as a staff scientist, and previously served on the board of directors of Bionovo, a public company developing novel therapeutics for breast cancer and women’s health.

“We are very excited to have someone of Mimi’s caliber join us to assist with the recruitment of top leadership talent to our portfolio companies,” said Patrick Heron, Managing General Partner with the Frazier Life Sciences team. “She brings not only a great Rolodex from her search experience, but also a scientific depth and entrepreneurial history that will allow her to work effectively with start-up teams.”

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.2 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.